Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALPNNYSE:IBIONASDAQ:IMNMNASDAQ:NXTCNASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shs2 shsIBIOiBio$0.75-1.7%$0.85$0.64▼$6.89$12.39M0.96842,430 shs726,900 shsIMNMImmunome$8.47-8.9%$8.64$5.15▼$16.81$736.98M1.94887,027 shs1.18 million shsNXTCNextCure$0.44-5.2%$0.48$0.22▼$1.82$12.23M1.07126,926 shs68,662 shsVTGNVistaGen Therapeutics$2.01+0.5%$2.29$1.90▼$4.21$58.61M0.7176,478 shs168,018 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%IBIOiBio+1.07%+7.12%-0.57%-80.48%-63.83%IMNMImmunome+6.04%+6.41%+4.97%+48.56%-23.14%NXTCNextCure+2.22%-2.13%-5.02%+5.26%-71.07%VTGNVistaGen Therapeutics+1.52%+2.04%-20.63%-14.53%-42.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune SciencesN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.6554 of 5 stars3.50.00.00.01.80.00.6IMNMImmunome2.2494 of 5 stars3.52.00.00.02.22.50.0NXTCNextCure4.3844 of 5 stars3.53.00.04.31.91.71.3VTGNVistaGen Therapeutics1.7611 of 5 stars0.05.00.00.01.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences 0.00N/AN/AN/AIBIOiBio 3.00Buy$4.30473.41% UpsideIMNMImmunome 3.00Buy$23.33175.48% UpsideNXTCNextCure 3.00Buy$3.50702.75% UpsideVTGNVistaGen Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest VTGN, NXTC, ALPN, IBIO, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/18/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$56.52M78.85N/AN/A$4.85 per share13.40IBIOiBio$375K33.03N/AN/A$1.41 per share0.53IMNMImmunome$9.04M81.52N/AN/A$2.27 per share3.73NXTCNextCureN/AN/AN/AN/A$2.34 per shareN/AVTGNVistaGen Therapeutics$490K119.62N/AN/A$2.44 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AIMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)NXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)VTGNVistaGen Therapeutics-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)Latest VTGN, NXTC, ALPN, IBIO, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025VTGNVistaGen Therapeutics-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A9.569.56IBIOiBio0.051.761.76IMNMImmunomeN/A10.4910.49NXTCNextCureN/A10.2610.26VTGNVistaGen TherapeuticsN/A6.516.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%IBIOiBio7.90%IMNMImmunome44.58%NXTCNextCure42.65%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%IBIOiBio0.58%IMNMImmunome8.60%NXTCNextCure13.30%VTGNVistaGen Therapeutics1.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences14268.60 million39.58 millionOptionableIBIOiBio10016.52 million9.82 millionN/AIMNMImmunome4087.01 million79.53 millionOptionableNXTCNextCure9028.05 million24.32 millionOptionableVTGNVistaGen Therapeutics4029.16 million28.78 millionOptionableVTGN, NXTC, ALPN, IBIO, and IMNM HeadlinesRecent News About These CompaniesVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comWilliam Blair Issues Negative Forecast for VTGN EarningsJune 23, 2025 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comEquities Analysts Set Expectations for VTGN Q1 EarningsJune 21, 2025 | americanbankingnews.comWilliam Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)June 20, 2025 | theglobeandmail.comVistagen Therapeutics’ Earnings Call Highlights Progress and ChallengesJune 19, 2025 | tipranks.comWhat is William Blair's Forecast for VTGN Q1 Earnings?June 19, 2025 | marketbeat.comVistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William BlairJune 18, 2025 | marketbeat.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...June 18, 2025 | finance.yahoo.comVistagen Therapeutics Reports Progress in Clinical TrialsJune 17, 2025 | tipranks.comVistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comVistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSJune 17, 2025 | marketbeat.comVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | businesswire.comInsights into VistaGen Therapeutics's Upcoming EarningsJune 16, 2025 | benzinga.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look ForJune 16, 2025 | gurufocus.comVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025June 12, 2025 | businesswire.comVistagen Therapeutics (VTGN) to Release Earnings on TuesdayJune 3, 2025 | marketbeat.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTGN, NXTC, ALPN, IBIO, and IMNM Company DescriptionsAlpine Immune Sciences NASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.iBio NYSE:IBIO$0.75 -0.01 (-1.73%) Closing price 04:00 PM EasternExtended Trading$0.72 -0.03 (-3.85%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Immunome NASDAQ:IMNM$8.47 -0.83 (-8.92%) Closing price 04:00 PM EasternExtended Trading$8.54 +0.07 (+0.89%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.NextCure NASDAQ:NXTC$0.44 -0.02 (-5.22%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.01 (+2.06%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.VistaGen Therapeutics NASDAQ:VTGN$2.01 +0.01 (+0.50%) Closing price 04:00 PM EasternExtended Trading$2.01 0.00 (0.00%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
